Abstract PS3-11-22: Efficacy and safety of 12-week adjuvant docetaxel plus trastuzumab in patients with node-negative HER2-positive breast cancer (tumors ≤1cm): results from the SOBER prospective single-arm trial
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129664958
Cites:
Cited by:
Related to: